ストックスクリーナーアプリを入手
83.53
0.59%
0.06
前日終値:
$83.59
開ける：
$84.08
24時間の取引高:
6,247
Relative Volume:
0.01
時価総額：
$6.91B
収益：
$39.21M
当期純損益:
$-311.35M
株価収益率:
-22.70
EPS:
-3.6793
ネットキャッシュフロー:
$-234.34M
1週間 パフォーマンス:
-1.36%
1か月 パフォーマンス:
-3.15%
6か月 パフォーマンス:
+38.10%
1年 パフォーマンス:
+146.31%
1日の値動き範囲:
$84.03
$84.08
1週間の範囲:
$77.64
$85.39
52週間の値動き範囲:
$28.06
$103.00
Kymera Therapeutics Inc Stock (KYMR) Company Profile
名前
Kymera Therapeutics Inc
セクター
電話
857-285-5314
住所
500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN
Compare KYMR vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
KYMR
Kymera Therapeutics Inc
|
84.03 | 6.80B | 39.21M | -311.35M | -234.34M | -3.6793 |
VRTX
Vertex Pharmaceuticals Inc
|
428.12 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
705.22 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
800.76 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
305.58 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Kymera Therapeutics Inc Stock (KYMR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-16 | 再開されました | Jefferies | Buy |
| 2026-01-28 | 再開されました | Barclays | Overweight |
| 2026-01-06 | ダウングレード | Wolfe Research | Outperform → Peer Perform |
| 2025-11-03 | 再開されました | Guggenheim | Buy |
| 2025-10-24 | 繰り返されました | B. Riley Securities | Buy |
| 2025-10-21 | 開始されました | Mizuho | Outperform |
| 2025-09-18 | 繰り返されました | H.C. Wainwright | Buy |
| 2025-09-17 | 開始されました | Barclays | Overweight |
| 2025-09-16 | 開始されました | RBC Capital Mkts | Outperform |
| 2025-07-30 | 再開されました | B. Riley Securities | Buy |
| 2025-07-03 | 再開されました | Morgan Stanley | Overweight |
| 2025-06-03 | アップグレード | B. Riley Securities | Neutral → Buy |
| 2025-06-03 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2025-06-02 | アップグレード | BofA Securities | Neutral → Buy |
| 2025-05-20 | 再開されました | Stifel | Buy |
| 2025-03-13 | 開始されました | Citigroup | Buy |
| 2024-12-10 | 開始されました | BTIG Research | Buy |
| 2024-12-06 | 開始されました | BMO Capital Markets | Market Perform |
| 2024-12-02 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2024-11-18 | 開始されました | Stephens | Overweight |
| 2024-09-09 | 再開されました | Leerink Partners | Outperform |
| 2024-08-26 | アップグレード | Wolfe Research | Peer Perform → Outperform |
| 2024-04-22 | 開始されました | Oppenheimer | Outperform |
| 2024-02-15 | 開始されました | Wolfe Research | Peer Perform |
| 2024-01-04 | アップグレード | JP Morgan | Neutral → Overweight |
| 2024-01-03 | ダウングレード | BofA Securities | Buy → Neutral |
| 2023-12-19 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2023-06-30 | 開始されました | Truist | Buy |
| 2023-05-05 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2022-12-06 | ダウングレード | Credit Suisse | Outperform → Neutral |
| 2022-11-08 | 開始されました | Raymond James | Mkt Perform |
| 2022-08-15 | 開始されました | Jefferies | Buy |
| 2022-08-03 | 開始されました | Goldman | Buy |
| 2022-07-20 | 開始されました | SVB Leerink | Mkt Perform |
| 2022-04-28 | 開始されました | Credit Suisse | Outperform |
| 2022-03-10 | 開始されました | JP Morgan | Neutral |
| 2022-02-10 | 開始されました | Wells Fargo | Overweight |
| 2021-09-30 | 開始されました | B. Riley Securities | Neutral |
| 2021-09-30 | 開始されました | Stifel | Buy |
| 2021-09-10 | ダウングレード | BofA Securities | Buy → Neutral |
| 2021-05-21 | 開始されました | UBS | Buy |
| 2021-04-14 | 開始されました | Berenberg | Buy |
| 2020-12-04 | 開始されました | H.C. Wainwright | Buy |
| 2020-09-15 | 開始されました | BofA Securities | Neutral |
| 2020-09-15 | 開始されました | Cowen | Outperform |
| 2020-09-15 | 開始されました | Guggenheim | Buy |
| 2020-09-15 | 開始されました | Morgan Stanley | Equal-Weight |
すべてを表示
Kymera Therapeutics Inc (KYMR) 最新ニュース
Kymera Therapeutics to Participate in Upcoming May Investor Conferences - The Manila Times
Kymera lines up two May investor webcasts from Las Vegas and New York - Stock Titan
Kymera Therapeutics to Participate in Upcoming May Investor Conferences - GlobeNewswire Inc.
Kymera presents preclinical data for IBD drug candidate KT-579 - Investing.com UK
Kymera Therapeutics Presents New Preclinical IBD Data for KT-579, a First-in-Class, Oral IRF5 Degrader, at Digestive Disease Week - Investing News Network
Kymera presents preclinical data for IBD drug candidate KT-579 By Investing.com - Investing.com Australia
Equities Analysts Issue Forecasts for KYMR Q2 Earnings - MarketBeat
Oral bowel disease drug matched approved therapies in preclinical tests - Stock Titan
Kymera Therapeutics, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:KYMR) 2026-05-04 - Seeking Alpha
Kymera Therapeutics Q1 2026 earnings preview - MSN
Kymera Therapeutics, Inc. Rings the Nasdaq Stock Market Opening Bell in Celebration of its 10-Year Anniversary - Nasdaq
Kymera Therapeutics, Inc. Rings the Opening Bell in Celebration of its 10-Year Anniversary - Nasdaq
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates - Yahoo Finance
Understanding Momentum Shifts in (KYMR) - Stock Traders Daily
Analysts Offer Insights on Healthcare Companies: Bicycle Therapeutics (BCYC), Kymera Therapeutics (KYMR) and Teleflex (TFX) - The Globe and Mail
Kymera expects KT-579 phase I data in 2H 2026 while targeting KT-621 BROADEN2 enrollment completion by year-end - MSN
Analysts Offer Insights on Healthcare Companies: Illumina (ILMN), Axsome Therapeutics (AXSM) and Kymera Therapeutics (KYMR) - The Globe and Mail
Jennison Associates LLC Decreases Stock Position in Kymera Therapeutics, Inc. $KYMR - MarketBeat
Kymera Therapeutics (NASDAQ:KYMR) Upgraded to Hold at Wall Street Zen - MarketBeat
Morgan Stanley Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Maintains Target Price $119 - Moomoo
KYMR Q1 Earnings Top Estimates, Revenues Gain on GILD Collaboration - Yahoo Finance
HC Wainwright & Co. Maintains Kymera Therapeutics (KYMR) Buy Recommendation - MSN
Kymera Therapeutics, Inc. (KYMR) reports Q1 loss, tops revenue estimates - MSN
Kymera Q1 2026 slides: immunology pipeline advances, revenue surges By Investing.com - Investing.com Australia
Kymera Therapeutics Inc (KYMR) Q1 2026 Earnings Call Highlights: Strategic Partnerships and Financial Resilience - GuruFocus
KYMR SWOT Analysis: Financial Challenges and Growth Potential Re - GuruFocus
Kymera Therapeutics (NASDAQ:KYMR) Announces Quarterly Earnings Results, Beats Expectations By $0.18 EPS - MarketBeat
Kymera Therapeutics Q1 2026 Earnings Call Transcript - MarketBeat
Key Risks and Forward-Looking Statements in Kymera Therapeutics, Inc. Q1 2026 10-Q Report - Minichart
Kymera Therapeutics Q1 Earnings Call Highlights - MarketBeat
Kymera Therapeutics Reports Q1 2026 Financial Results, Highlights Pipeline Progress and $1.55B Cash Runway into 2029 - Minichart
Kymera shifts KT-579 data to 2H 2026, keeps KT-621 on track - MSN
Kymera Therapeutics Releases Q1 2026 Financial Results - AlphaStreet
Earnings call transcript: Kymera Therapeutics beats Q1 2026 earnings forecasts By Investing.com - Investing.com Australia
Kymera Therapeutics (KYMR) Achieves Strong Q1 Revenue Performanc - GuruFocus
Earnings call transcript: Kymera Therapeutics beats Q1 2026 earnings forecasts - Investing.com
Kymera Therapeutics Shares Fall After Q1 Loss Narrows, Collaboration Revenue Rises - Moomoo
Kymera Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business Update - Investing News Network
Kymera Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Is Kymera Therapeutics (KYMR) 418.1% Overvalued After Q1 2026 Be - GuruFocus
Kymera Therapeutics, Inc. (KYMR) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
Kymera Therapeutics (NASDAQ:KYMR) Soars on Q1 2026 Revenue and EPS Beat - ChartMill
Earnings Flash (KYMR) Kymera Therapeutics Posts Q1 Net Loss $0.71 a Share, vs. FactSet Est of $0.88 Loss - marketscreener.com
Earnings Flash (KYMR) Kymera Therapeutics, Inc. Reports Q1 Revenue $34.4M, vs. FactSet Est of $8.3M - marketscreener.com
Kymera Therapeutics (NASDAQ: KYMR) grows collaboration revenue but stays in loss - Stock Titan
Kymera Therapeutics (NASDAQ: KYMR) Q1 2026 results and $45M Gilead milestone - Stock Titan
Press Release: Kymera Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business Update - Moomoo
Pictet Asset Management Holding SA Has $37.79 Million Stake in Kymera Therapeutics, Inc. $KYMR - MarketBeat
Kymera Therapeutics (KYMR) Q1 2026 Deepening Losses Test Bullish Revenue Growth Narrative - Sahm
Insider Selling: Kymera Therapeutics (NASDAQ:KYMR) CEO Sells 30,000 Shares of Stock - MarketBeat
Kymera Therapeutics CEO Nello Mainolfi sells $2.4m in stock By Investing.com - Investing.com Nigeria
Kymera Therapeutics Inc (KYMR) 財務データ
収益
当期純利益
現金流量
EPS
0.14%
2.09%
大文字化:
|
ボリューム (24 時間):